| Name | Title | Contact Details |
|---|
Health at Home is a Delray Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dr. Katie Rodan and Dr. Kathy Fields met at Stanford University during their dermatology residency bonding over their personal struggles with acne and an understanding of how skin issues impact self-esteem and self-confidence. They combined their personal connection and professional expertise into a shared mission: to provide everyone with life-changing skincareTM that deliver real results! Today, Rodan + Fields has grown from its humble beginnings in Dr. Katie Rodan`s kitchen to the #1 skincare brand in the U.S. in 2016.* We combine our innovative products with a high-tech, high-touch approach, and as a result, more than a million customers have experienced the benefits of Rodan + Fields. We are transforming skincare, and we welcome your big ideas to fuel our ambitious growth plans! If you are looking for a life-changing career opportunity, we`ve got your prescription. At Rodan + Fields, you will be challenged to make an impact, inspired to do more, and rewarded for your contributions.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Kahl and Associates is a Olympia, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.